丹麦制药巨头诺和诺德(NVO)近日传来一连串利好消息,公司股价在盘前出现大涨。
上周,诺和诺德在上海进博会上展示了其旗舰减肥药Wegovy的口服和注射版本,吸引了全球目光。这反映了市场对公司在减肥药领域的高度期待。与此同时,诺和诺德还宣布与Ascendis Pharma达成合作,开发针对肥胖和糖尿病的长效GLP-1受体激动剂,这再次彰显了该公司在该领域的持续布局实力。
更为关键的是,诺和诺德于周一发布了2024年第三季度财报。财报数据显示,公司第三季度净利润273.01亿丹麦克朗,同比增长21%,好于市场预期的267亿丹麦克朗。这主要得益于其热销减肥药Wegovy销量在全球范围内激增。
分析人士指出,随着更多保险公司开始报销降肥药物费用,加之诺和诺德致力于提高产能以满足旺盛需求,Wegovy未来销量有望持续攀升,这将是公司利润增长的重要动力。
尽管其他制药企业如阿斯利康、维京治疗等也纷纷推出新的减肥药或在研药物,但效果是否能超过诺和诺德的产品尚待观察。目前看来,诺和诺德仍然保持着减肥药市场领导者的地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.